These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34782922)

  • 1. Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus.
    Wohlfarth D; Frehtman V; Müller M; Vogel M; Phan LMP; Brunecker A; Leuchs B
    Appl Microbiol Biotechnol; 2021 Dec; 105(24):9113-9124. PubMed ID: 34782922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an HSV-1 production process involving serum-reduced culturing and bead-to-bead transfer.
    Wang H; Hu X; Zhang M; Yang L; Xu Y; Gu X; Jiang J; Hu W
    Appl Microbiol Biotechnol; 2024 Jun; 108(1):383. PubMed ID: 38896301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro.
    Geiss C; Kis Z; Leuchs B; Frank-Stöhr M; Schlehofer JR; Rommelaere J; Dinsart C; Lacroix J
    Viruses; 2017 Oct; 9(10):. PubMed ID: 29039746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
    Frehtman V; Wohlfarth D; Müller M; Krebs O; Leuchs B
    Appl Microbiol Biotechnol; 2023 Aug; 107(15):4777-4787. PubMed ID: 37209160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing elements of a synthetic biology platform for Vaccinia virus production: BioBrick™ design, serum-free virus production and microcarrier-based cultivation of CV-1 cells.
    Liu S; Ruban L; Wang Y; Zhou Y; Nesbeth DN
    Heliyon; 2017 Feb; 3(2):e00238. PubMed ID: 28203643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.
    Lesch HP; Heikkilä KM; Lipponen EM; Valonen P; Müller A; Räsänen E; Tuunanen T; Hassinen MM; Parker N; Karhinen M; Shaw R; Ylä-Herttuala S
    Hum Gene Ther; 2015 Aug; 26(8):560-71. PubMed ID: 26176404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.
    Göbel S; Jaén KE; Dorn M; Neumeyer V; Jordan I; Sandig V; Reichl U; Altomonte J; Genzel Y
    Biotechnol Bioeng; 2023 Sep; 120(9):2639-2657. PubMed ID: 36779302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
    Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
    Viruses; 2016 May; 8(5):. PubMed ID: 27213425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
    Bretscher C; Marchini A
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
    Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
    Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
    Ferreira T; Kulkarni A; Bretscher C; Nazarov PV; Hossain JA; Ystaas LAR; Miletic H; Röth R; Niesler B; Marchini A
    Viruses; 2022 May; 14(5):. PubMed ID: 35632759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
    Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing efficiency of human mesenchymal stromal cell culture by optimization of microcarrier concentration and design of medium feed.
    Chen AK; Chew YK; Tan HY; Reuveny S; Weng Oh SK
    Cytotherapy; 2015 Feb; 17(2):163-73. PubMed ID: 25304664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions.
    Rourou S; van der Ark A; van der Velden T; Kallel H
    Vaccine; 2007 May; 25(19):3879-89. PubMed ID: 17307281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor.
    Rourou S; van der Ark A; Majoul S; Trabelsi K; van der Velden T; Kallel H
    Appl Microbiol Biotechnol; 2009 Nov; 85(1):53-63. PubMed ID: 19521697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.